OSAKA/TOKYO -- Japanese drugmaker Shionogi said Wednesday that it will acquire Torii Pharmaceutical and other assets from Japan Tobacco in a deal worth around 160 billion yen ($1.1 billion ...

Growth is expected from the HIV franchise, global expansion of Xocova, and stabilization of ... in business strategies and emphasized that Shionogi will focus on new drug launches in China ...

Statistically Significant Reduction in Viral Load Confirmed in Clinical Trial Primary Endpoint Achieved In the highest dose group, there was an 88.94% reduction in viral load (P<0.0001) OSAKA, Japan, ...

Shionogi & Co., Ltd. has a beta of 0.21 ... Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an ...

Shionogi has prior experience in Covid-19 drug development. In 2024, the company’s antiviral drug Xocova (ensitrelvir) received full approval in Japan, but the Phase III SCORPIO-HR trial ...

Japanese drugmaker Shionogi (OTCPK:SGIOY) said a Phase 3 study has shown its antiviral drug Xocova was effective in reducing the risk of developing symptomatic COVID-19 infection in those exposed ...

Ensitrelvir, known commercially as Xocova, showed a statistically significant reduction in participants with symptomatic infection after exposure to household contacts with COVID, Shionogi said in ...

TOKYO (Reuters) – Japan’s Shionogi & Co said on Tuesday a global, late-stage study showed its pill-based treatment for COVID-19 was effective in reducing transmission of the disease. Ensitrelvir, ...

Michael N. Dudley, PharmD, President and CEO of Qpex Biopharma SAN DIEGO—Shionogi plans to create its first discovery lab in the United States, with a focus on antimicrobial and pandemic ...

Shionogi's ensitrelvir pill for Covid-19 missed the trial endpoint but demonstrated a strong antiviral effect. Xocova aimed for $2B annual sales and early 2025 US approval, competing with Pfizer's ...

WHY IT'S IMPORTANT Shionogi said previously it expected the pill, known commercially as Xocova, to deliver $2 billion in annual sales if it secured U.S. approval. Xocova would compete with Pfizer ...

Outside Japan, Xocova is also approved in Singapore. Sanofi keeps Novavax afloat with $1.2B bet on its vaccine platform Despite the misfire in SCORPIO-HR, Shionogi said that a pre-defined ...